JNJ 56136379

Drug Profile

JNJ 56136379

Alternative Names: JNJ-379; JNJ-56136379

Latest Information Update: 21 Mar 2017

Price : $50

At a glance

  • Originator Janssen Sciences Ireland UC
  • Class Antivirals
  • Mechanism of Action Capsid protein inhibitors; Viral core protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Hepatitis B

Most Recent Events

  • 04 Feb 2017 Janssen Research & Development completes a phase I trial in Healthy volunteers in USA (PO, Tablet) (NCT02933580)
  • 11 Nov 2016 Interim adverse events and pharmacokinetics data of a phase I trial in Hepatitis B presented at The Liver Meeting® 2016: 67th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD - 2016)
  • 12 Oct 2016 Phase-I clinical trials in Hepatitis B (In volunteers) in USA (PO) (NCT02933580)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top